Agios Pharmaceuticals (NASDAQ:AGIO) Posts Earnings Results, Misses Expectations By $0.05 EPS

Agios Pharmaceuticals (NASDAQ:AGIO) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05), Zacks reports. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%.

Agios Pharmaceuticals Stock Up 4.3 %

AGIO stock opened at $35.22 on Friday. The company has a market capitalization of $2.02 billion, a P/E ratio of 3.11 and a beta of 0.88. The company has a 50-day simple moving average of $34.29 and a 200 day simple moving average of $43.03. Agios Pharmaceuticals has a fifty-two week low of $26.66 and a fifty-two week high of $62.58.

Insider Buying and Selling

In related news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares of the company’s stock, valued at $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 4.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Scotiabank boosted their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. Finally, Royal Bank of Canada boosted their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $56.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.